Regulatory Network in Protein Phosphorylation
[Home] [About] [Browse Kinome] [Phosphorylation Prediction] [Expression Analysis] [Statistics] [Help] Version 1.0

[Back to Kinase CK2a1]
Substrate: TOP2A

Description: DNA topoisomerase 2-alpha (EC 5.99.1.3) (DNA topoisomerase II, alphaisozyme).

Synonyms: TOP2

UniprotKB/SwissProt: TOP2A_HUMAN (P11388)

Function: Control of topological states of DNA by transient breakage and subsequent rejoining of DNA strands. Topoisomerase II makes double-strand breaks.

Other Modifications: View all modification sites in dbPTM

Protein Subcellular Localization: Cytoplasm. Nucleus, nucleoplasm. Note=Generally located in the nucleoplasm.
PDB:1LWZ
Protein Domain and Phosphorylation Sites:

The phosphorylated sites of TOP2A

No.SubstrateUniProtKB IDPositionPhosphoPeptideSolvent AccessibilityCatalytic kinaseSourceComputational Annotation of Catalytic KinaseInteracting PartnersExpression Analysis
1TOP2ATOP2A_HUMANS4--MEV S PLQPV 24.16% Swiss-Prot 55.0 View   
2TOP2ATOP2A_HUMANS4--MEV S PLQPV 24.16% Phospho.ELM 7.0View   
3TOP2ATOP2A_HUMANS29AKKRL S VERIY 26.43%PKCa HPRD:00536(in vitro;in vivo)  ViewAnalyzing
4TOP2ATOP2A_HUMANS29AKKRL S VERIY 26.43%PKCb HPRD:00536(in vitro;in vivo)  ViewAnalyzing
5TOP2ATOP2A_HUMANS29AKKRL S VERIY 26.43%PKC_group Phospho.ELM 7.0 ViewAnalyzing
6TOP2ATOP2A_HUMANS29AKKRL S VERIY 26.43%PKCg HPRD:00536(in vitro;in vivo)  ViewAnalyzing
7TOP2ATOP2A_HUMANS29AKKRL S VERIY 26.43% Swiss-Prot 55.0 View   
8TOP2ATOP2A_HUMANS1106EENEE S DNEKE 39.29% Phospho.ELM 7.0View   
9TOP2ATOP2A_HUMANS1106EENEE S DNEKE 39.29% Swiss-Prot 55.0 View   
10TOP2ATOP2A_HUMANS1106EENEE S DNEKE 39.29% HPRD:00536(in vitro;in vivo)View   
11TOP2ATOP2A_HUMANS1213AEVLP S PRGQR 24.06%CDC2 HPRD:00536(in vitro;in vivo)  ViewAnalyzing
12TOP2ATOP2A_HUMANS1213AEVLP S PRGQR 24.06%Erk1(MAPK3) Phospho.ELM 7.0 ViewAnalyzing
13TOP2ATOP2A_HUMANS1213AEVLP S PRGQR 24.06% HPRD:00536(in vivo)View   
14TOP2ATOP2A_HUMANS1213AEVLP S PRGQR 24.06%Erk2(MAPK1) Phospho.ELM 7.0 ViewAnalyzing
15TOP2ATOP2A_HUMANS1213AEVLP S PRGQR 24.06% Swiss-Prot 55.0 View   
16TOP2ATOP2A_HUMANS1213AEVLP S PRGQR 24.06%CDC2(CDK1) Phospho.ELM 7.0 ViewAnalyzing
17TOP2ATOP2A_HUMANS1247ENTEG S PQEDG 19.71%CDC2 HPRD:00536(in vitro;in vivo)  ViewAnalyzing
18TOP2ATOP2A_HUMANS1247ENTEG S PQEDG 19.71% Swiss-Prot 55.0 View   
19TOP2ATOP2A_HUMANS1247ENTEG S PQEDG 19.71%Erk1(MAPK3) Phospho.ELM 7.0 ViewAnalyzing
20TOP2ATOP2A_HUMANS1247ENTEG S PQEDG 19.71%CDC2(CDK1) Phospho.ELM 7.0 ViewAnalyzing
21TOP2ATOP2A_HUMANS1247ENTEG S PQEDG 19.71%Erk2(MAPK1) Phospho.ELM 7.0 ViewAnalyzing
22TOP2ATOP2A_HUMANS1247ENTEG S PQEDG 19.71% HPRD:00536(in vivo)View   
23TOP2ATOP2A_HUMANS1295KRNPW S DSESD 32.30% Phospho.ELM 7.0View   
24TOP2ATOP2A_HUMANS1295KRNPW S DSESD 32.30% Swiss-Prot 55.0 View   
25TOP2ATOP2A_HUMANS1295KRNPW S DSESD 32.30% HPRD:00536(in vivo)View   
26TOP2ATOP2A_HUMANS1297NPWSD S ESDRS 33.22% HPRD:00536(in vivo)View   
27TOP2ATOP2A_HUMANS1297NPWSD S ESDRS 33.22% Phospho.ELM 7.0View   
28TOP2ATOP2A_HUMANS1297NPWSD S ESDRS 33.22% Swiss-Prot 55.0 View   
29TOP2ATOP2A_HUMANS1332TMDLD S DEDFS 50.63% Phospho.ELM 7.0View   
30TOP2ATOP2A_HUMANS1332TMDLD S DEDFS 50.63% Swiss-Prot 55.0 View   
31TOP2ATOP2A_HUMANS1337SDEDF S DFDEK 50.09% Phospho.ELM 7.0View   
32TOP2ATOP2A_HUMANS1337SDEDF S DFDEK 50.09% Swiss-Prot 55.0 View   
33TOP2ATOP2A_HUMANT1343DFDEK T DDEDF 46.78% Swiss-Prot 55.0 View   
34TOP2ATOP2A_HUMANT1343DFDEK T DDEDF 46.78%CK2a1 HPRD:00536(in vivo)  ViewAnalyzing
35TOP2ATOP2A_HUMANT1343DFDEK T DDEDF 46.78%CK2a1-rs HPRD:00536(in vivo)  ViewAnalyzing
36TOP2ATOP2A_HUMANT1343DFDEK T DDEDF 46.78%CK2_group Phospho.ELM 7.0 ViewAnalyzing
37TOP2ATOP2A_HUMANT1343DFDEK T DDEDF 46.78%PKCb(PKC beta) Phospho.ELM 7.0 ViewAnalyzing
38TOP2ATOP2A_HUMANS1351EDFVP S DASPP 40.27% Phospho.ELM 7.0View   
39TOP2ATOP2A_HUMANS1351EDFVP S DASPP 40.27% Swiss-Prot 55.0 View   
40TOP2ATOP2A_HUMANS1351EDFVP S DASPP 40.27% HPRD:00536(in vivo)View   
41TOP2ATOP2A_HUMANS1354VPSDA S PPKTK 46.88%Erk2(MAPK1) Phospho.ELM 7.0 ViewAnalyzing
42TOP2ATOP2A_HUMANS1354VPSDA S PPKTK 46.88% HPRD:00536(in vivo)View   
43TOP2ATOP2A_HUMANS1354VPSDA S PPKTK 46.88%Erk1(MAPK3) Phospho.ELM 7.0 ViewAnalyzing
44TOP2ATOP2A_HUMANS1354VPSDA S PPKTK 46.88%CDC2 HPRD:00536(in vitro;in vivo)  ViewAnalyzing
45TOP2ATOP2A_HUMANS1354VPSDA S PPKTK 46.88% Swiss-Prot 55.0 View   
46TOP2ATOP2A_HUMANS1354VPSDA S PPKTK 46.88%CDC2(CDK1) Phospho.ELM 7.0 ViewAnalyzing
47TOP2ATOP2A_HUMANS1361PKTKT S PKLSN 22.92%CDC2 HPRD:00536(in vitro;in vivo)  ViewAnalyzing
48TOP2ATOP2A_HUMANS1361PKTKT S PKLSN 22.92%Erk1(MAPK3) Phospho.ELM 7.0 ViewAnalyzing
49TOP2ATOP2A_HUMANS1361PKTKT S PKLSN 22.92%CDC2(CDK1) Phospho.ELM 7.0 ViewAnalyzing
50TOP2ATOP2A_HUMANS1361PKTKT S PKLSN 22.92%Erk2(MAPK1) Phospho.ELM 7.0 ViewAnalyzing
51TOP2ATOP2A_HUMANS1374LKPQK S VVSDL 23.62% Swiss-Prot 55.0 View   
52TOP2ATOP2A_HUMANS1374LKPQK S VVSDL 23.62% Phospho.ELM 7.0View   
53TOP2ATOP2A_HUMANS1377QKSVV S DLEAD 34.03% HPRD:00536(in vivo)View   
54TOP2ATOP2A_HUMANS1377QKSVV S DLEAD 34.03%CK2a1 HPRD:00536(in vitro;in vivo)  ViewAnalyzing
55TOP2ATOP2A_HUMANS1377QKSVV S DLEAD 34.03%CK2a1(CK2 alpha) Phospho.ELM 7.0 ViewAnalyzing
56TOP2ATOP2A_HUMANS1377QKSVV S DLEAD 34.03%CK2a1-rs HPRD:00536(in vitro;in vivo)  ViewAnalyzing
57TOP2ATOP2A_HUMANS1377QKSVV S DLEAD 34.03%CK2_group Phospho.ELM 7.0 ViewAnalyzing
58TOP2ATOP2A_HUMANS1377QKSVV S DLEAD 34.03% Swiss-Prot 55.0 View   
59TOP2ATOP2A_HUMANS1387DDVKG S VPLSS 18.16% Phospho.ELM 7.0View   
60TOP2ATOP2A_HUMANS1387DDVKG S VPLSS 18.16% HPRD:00536(in vivo)View   
61TOP2ATOP2A_HUMANS1387DDVKG S VPLSS 18.16% Swiss-Prot 55.0 View   
62TOP2ATOP2A_HUMANS1393VPLSS S PPATH 31.37%Erk1(MAPK3) Phospho.ELM 7.0 ViewAnalyzing
63TOP2ATOP2A_HUMANS1393VPLSS S PPATH 31.37%CDC2(CDK1) Phospho.ELM 7.0 ViewAnalyzing
64TOP2ATOP2A_HUMANS1393VPLSS S PPATH 31.37% Swiss-Prot 55.0 View   
65TOP2ATOP2A_HUMANS1393VPLSS S PPATH 31.37%Erk2(MAPK1) Phospho.ELM 7.0 ViewAnalyzing
66TOP2ATOP2A_HUMANS1393VPLSS S PPATH 31.37%CDC2 HPRD:00536(in vitro;in vivo)  ViewAnalyzing
67TOP2ATOP2A_HUMANS1469RKRKP S TSDDS 43.51% HPRD:00536(in vivo)View   
68TOP2ATOP2A_HUMANS1469RKRKP S TSDDS 43.51%CK2a1 HPRD:00536(in vitro)  ViewAnalyzing
69TOP2ATOP2A_HUMANS1469RKRKP S TSDDS 43.51%CK2_group Swiss-Prot 55.0  ViewAnalyzing
70TOP2ATOP2A_HUMANS1469RKRKP S TSDDS 43.51%CK2a1-rs HPRD:00536(in vitro)  ViewAnalyzing
71TOP2ATOP2A_HUMANT1470KRKPS T SDDSD 44.71% Swiss-Prot 55.0 View   
72TOP2ATOP2A_HUMANS1471RKPST S DDSDS 43.70% Swiss-Prot 55.0 View   
73TOP2ATOP2A_HUMANS1474STSDD S DSNFE 48.18% Swiss-Prot 55.0 View   
74TOP2ATOP2A_HUMANS1474STSDD S DSNFE 48.18% HPRD:00536(in vivo)View   
75TOP2ATOP2A_HUMANS1474STSDD S DSNFE 48.18% Phospho.ELM 7.0View   
76TOP2ATOP2A_HUMANS1525KYLEE S DEDDL 36.60%CK2a1(CK2 alpha) Phospho.ELM 7.0 ViewAnalyzing
77TOP2ATOP2A_HUMANS1525KYLEE S DEDDL 36.60%CK2a1 HPRD:00536(in vitro;in vivo)  ViewAnalyzing
78TOP2ATOP2A_HUMANS1525KYLEE S DEDDL 36.60%CK2a1-rs HPRD:00536(in vitro;in vivo)  ViewAnalyzing
79TOP2ATOP2A_HUMANS1525KYLEE S DEDDL 36.60%CK2_group Phospho.ELM 7.0 ViewAnalyzing
80TOP2ATOP2A_HUMANS1525KYLEE S DEDDL 36.60% Swiss-Prot 55.0 View